GlobeNewswire: AC Immune SA Contains the last 10 of 197 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T19:17:20ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/14/2846139/0/en/AC-Immune-Reports-Full-Year-2023-Financial-Results-and-Provides-a-Corporate-Update.html?f=22&fvtc=4&fvtv=30444AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update2024-03-14T11:00:00Z<![CDATA[AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update]]>https://www.globenewswire.com/news-release/2024/02/22/2833535/0/en/AC-Immune-Announces-Upcoming-Presentations-at-AD-PD-2024.html?f=22&fvtc=4&fvtv=30444AC Immune Announces Upcoming Presentations at AD/PD™ 20242024-02-22T12:00:00Z<![CDATA[AC Immune Announces Upcoming Presentations at AD/PD™ 2024]]>https://www.globenewswire.com/news-release/2024/01/22/2812913/0/en/AC-Immune-to-Regain-Global-Rights-to-Crenezumab-and-Semorinemab.html?f=22&fvtc=4&fvtv=30444AC Immune to Regain Global Rights to Crenezumab and Semorinemab2024-01-22T12:00:00Z<![CDATA[AC Immune to Regain Global Rights to Crenezumab and Semorinemab]]>https://www.globenewswire.com/news-release/2024/01/03/2803284/0/en/AC-Immune-Progress-Update-on-Phase-2-Active-Immunotherapy-Clinical-Pipeline-for-Alzheimer-s-and-Parkinson-diseases.html?f=22&fvtc=4&fvtv=30444AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases2024-01-03T13:10:00Z<![CDATA[AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases]]>https://www.globenewswire.com/news-release/2023/12/15/2797008/0/en/AC-Immune-Announces-Pricing-of-Underwritten-Offering-of-Common-Shares.html?f=22&fvtc=4&fvtv=30444AC Immune Announces Pricing of Underwritten Offering of Common Shares 2023-12-15T12:56:11Z<![CDATA[AC Immune Announces Pricing of Underwritten Offering of Common Shares]]>https://www.globenewswire.com/news-release/2023/12/15/2796982/0/en/AC-Immune-s-Targeted-Anti-pTau-Active-Immunotherapy-for-Alzheimer-s-Disease-Advances-into-Phase-2b-Trial.html?f=22&fvtc=4&fvtv=30444AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial2023-12-15T12:22:52Z<![CDATA[AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial]]>https://www.globenewswire.com/news-release/2023/12/01/2789221/0/en/AC-Immune-Strengthens-Management-Appoints-Madiha-Derouazi-as-CSO-and-Christopher-Roberts-as-CFO.html?f=22&fvtc=4&fvtv=30444AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO2023-12-01T12:00:00Z<![CDATA[AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO]]>Dr. Madiha Derouazi appointed as new CSO of AC ImmuneAC Immune appoints Madiha Derouazi as CSO Christopher Roberts confirmed in CFO role on a permanent basisAC Immune appoints Christopher Roberts as CFOhttps://www.globenewswire.com/news-release/2023/11/07/2774887/0/en/AC-Immune-to-Present-at-the-Jefferies-2023-London-Healthcare-Conference.html?f=22&fvtc=4&fvtv=30444AC Immune to Present at the Jefferies 2023 London Healthcare Conference2023-11-07T12:00:00Z<![CDATA[AC Immune to Present at the Jefferies 2023 London Healthcare Conference]]>https://www.globenewswire.com/news-release/2023/11/03/2773089/0/en/AC-Immune-Reports-Third-Quarter-2023-Financial-Results-and-Provides-a-Corporate-Update.html?f=22&fvtc=4&fvtv=30444AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update2023-11-03T11:00:00Z<![CDATA[AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update]]>https://www.globenewswire.com/news-release/2023/11/02/2772091/0/en/AC-Immune-to-Host-KOL-Webinar-on-Amyloid-Plaque-PET-Imaging-in-Alzheimer-s-Disease-as-a-Surrogate-of-Clinical-Efficacy-on-November-9-2023.html?f=22&fvtc=4&fvtv=30444AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 20232023-11-02T11:00:00Z<![CDATA[AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023]]>